Viatris (VTRS) Competitors

$17.17 -0.22 (-1.27%)

Closing price 04:00 PM Eastern

Extended Trading

$17.22 +0.05 (+0.27%)

As of 05:15 PM Eastern

VTRS vs. PFE, TAK, ARGX, TEVA, and ONC

Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Pfizer (PFE), Takeda Pharmaceutical (TAK), argenex (ARGX), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). These companies are all part of the "medical" sector.

How does Viatris compare to Pfizer?

Pfizer (NYSE:PFE) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Pfizer has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.34	$7.77B	$1.31	19.58
Viatris	$14.30B	1.40	-$3.51B	-$0.26	N/A

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.7%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.8%. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -184.6% of its earnings in the form of a dividend. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Pfizer had 66 more articles in the media than Viatris. MarketBeat recorded 84 mentions for Pfizer and 18 mentions for Viatris. Pfizer's average media sentiment score of 0.83 beat Viatris' score of 0.51 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	45 Very Positive mention(s)	7 Positive mention(s)	17 Neutral mention(s)	7 Negative mention(s)	4 Very Negative mention(s)	Positive
Viatris	1 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer currently has a consensus price target of $28.74, suggesting a potential upside of 12.05%. Viatris has a consensus price target of $15.71, suggesting a potential downside of 8.48%. Given Pfizer's higher possible upside, equities analysts plainly believe Pfizer is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	3 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.23
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Pfizer has a net margin of 11.83% compared to Viatris' net margin of -24.58%. Pfizer's return on equity of 19.44% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Viatris	-24.58%	18.11%	7.29%

68.4% of Pfizer shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Pfizer beats Viatris on 16 of the 20 factors compared between the two stocks.

How does Viatris compare to Takeda Pharmaceutical?

Viatris (NASDAQ:VTRS) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Viatris has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500.

In the previous week, Viatris had 11 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 18 mentions for Viatris and 7 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.74 beat Viatris' score of 0.51 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viatris presently has a consensus price target of $15.71, suggesting a potential downside of 8.48%. Given Viatris' higher probable upside, research analysts plainly believe Viatris is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Takeda Pharmaceutical has a net margin of 2.58% compared to Viatris' net margin of -24.58%. Viatris' return on equity of 18.11% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-24.58%	18.11%	7.29%
Takeda Pharmaceutical	2.58%	10.60%	5.21%

Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.40	-$3.51B	-$0.26	N/A
Takeda Pharmaceutical	$4.46T	0.01	$712.33M	$0.24	68.69

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.8%. Takeda Pharmaceutical pays an annual dividend of $0.50 per share and has a dividend yield of 3.0%. Viatris pays out -184.6% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 208.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

Viatris beats Takeda Pharmaceutical on 10 of the 18 factors compared between the two stocks.

How does Viatris compare to argenex?

Viatris (NASDAQ:VTRS) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Viatris has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

In the previous week, argenex had 3 more articles in the media than Viatris. MarketBeat recorded 21 mentions for argenex and 18 mentions for Viatris. Viatris' average media sentiment score of 0.51 beat argenex's score of 0.39 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	8 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.9% of Viatris shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Viatris presently has a consensus price target of $15.71, suggesting a potential downside of 8.48%. argenex has a consensus price target of $1,017.78, suggesting a potential upside of 30.12%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

argenex has a net margin of 30.42% compared to Viatris' net margin of -24.58%. argenex's return on equity of 38.51% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-24.58%	18.11%	7.29%
argenex	30.42%	38.51%	32.59%

argenex has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.40	-$3.51B	-$0.26	N/A
argenex	$4.15B	11.71	$1.29B	$19.52	40.07

Summary

argenex beats Viatris on 13 of the 17 factors compared between the two stocks.

How does Viatris compare to Teva Pharmaceutical Industries?

Viatris (NASDAQ:VTRS) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Viatris has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

In the previous week, Teva Pharmaceutical Industries had 14 more articles in the media than Viatris. MarketBeat recorded 32 mentions for Teva Pharmaceutical Industries and 18 mentions for Viatris. Teva Pharmaceutical Industries' average media sentiment score of 0.65 beat Viatris' score of 0.51 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	15 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

79.9% of Viatris shares are owned by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.8%. Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 2.8%. Viatris pays out -184.6% of its earnings in the form of a dividend. Teva Pharmaceutical Industries pays out 76.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Viatris presently has a consensus price target of $15.71, suggesting a potential downside of 8.48%. Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 16.98%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Viatris' net margin of -24.58%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-24.58%	18.11%	7.29%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Teva Pharmaceutical Industries has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.40	-$3.51B	-$0.26	N/A
Teva Pharmaceutical Industries	$17.35B	2.37	$1.41B	$1.33	26.85

Summary

Teva Pharmaceutical Industries beats Viatris on 15 of the 18 factors compared between the two stocks.

How does Viatris compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

In the previous week, BeOne Medicines and BeOne Medicines both had 18 articles in the media. Viatris' average media sentiment score of 0.51 beat BeOne Medicines' score of 0.26 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	1 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.

BeOne Medicines has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.41	$286.93M	$2.52	123.86
Viatris	$14.30B	1.40	-$3.51B	-$0.26	N/A

BeOne Medicines has a net margin of 8.94% compared to Viatris' net margin of -24.58%. Viatris' return on equity of 18.11% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.55%	6.96%
Viatris	-24.58%	18.11%	7.29%

BeOne Medicines currently has a consensus price target of $391.00, indicating a potential upside of 25.27%. Viatris has a consensus price target of $15.71, indicating a potential downside of 8.48%. Given BeOne Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe BeOne Medicines is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

BeOne Medicines beats Viatris on 10 of the 16 factors compared between the two stocks.

Get Viatris News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTRS vs. The Competition

Export

Metric	Viatris	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.99B	$8.21B	$6.18B	$12.29B
Dividend Yield	3.01%	2.92%	2.78%	5.25%
P/E Ratio	-5.80	22.89	28.70	27.27
Price / Sales	1.40	17.54	506.88	64.14
Price / Cash	2.16	82.13	43.30	53.97
Price / Book	1.34	4.79	10.00	6.82
Net Income	-$3.51B	$183.43M	$3.54B	$332.87M
7 Day Performance	N/A	N/A	N/A	0.09%
1 Month Performance	26.53%	6.03%	4.67%	7.37%
1 Year Performance	88.79%	2.16%	40.47%	41.10%

Viatris Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTRS Viatris	1.8439 of 5 stars	$17.17 -1.3%	$15.71 -8.5%	+101.2%	$19.99B	$14.30B	N/A	30,000	Trending News Earnings Report Dividend Announcement Analyst Forecast
PFE Pfizer	4.1349 of 5 stars	$26.81 -0.7%	$28.48 +6.2%	+16.2%	$153.53B	$62.58B	19.72	75,000	Trending News Earnings Report Analyst Upgrade Options Volume Analyst Revision
TAK Takeda Pharmaceutical	1.0049 of 5 stars	$16.36 -1.7%	N/A	+10.3%	$52.92B	$30.09B	68.15	47,455	Upcoming Earnings
ARGX argenex	3.8452 of 5 stars	$783.74 +0.4%	$1,016.22 +29.7%	+26.5%	$48.52B	$4.25B	40.15	1,863	Trending News Earnings Report Analyst Forecast
TEVA Teva Pharmaceutical Industries	4.4742 of 5 stars	$31.31 +2.2%	$38.78 +23.9%	+105.3%	$35.23B	$17.26B	26.09	33,950	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTRS) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viatris (VTRS) Competitors

VTRS vs. PFE, TAK, ARGX, TEVA, and ONC

How does Viatris compare to Pfizer?

Summary

How does Viatris compare to Takeda Pharmaceutical?

Summary

How does Viatris compare to argenex?

Summary

How does Viatris compare to Teva Pharmaceutical Industries?

Summary

How does Viatris compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTRS vs. The Competition

Viatris Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viatris (VTRS) Competitors

VTRS vs. PFE, TAK, ARGX, TEVA, and ONC

How does Viatris compare to Pfizer?

Which has more risk & volatility, PFE or VTRS?

Which has better valuation & earnings, PFE or VTRS?

Is PFE or VTRS a better dividend stock?

Does the media prefer PFE or VTRS?

Do analysts rate PFE or VTRS?

Is PFE or VTRS more profitable?

Do insiders and institutionals hold more shares of PFE or VTRS?

Summary

How does Viatris compare to Takeda Pharmaceutical?

Do institutionals & insiders have more ownership in VTRS or TAK?

Which has more risk and volatility, VTRS or TAK?

Does the media prefer VTRS or TAK?

Do analysts prefer VTRS or TAK?

Is VTRS or TAK more profitable?

Which has better earnings and valuation, VTRS or TAK?

Is VTRS or TAK a better dividend stock?

Summary

How does Viatris compare to argenex?

Which has more volatility and risk, VTRS or ARGX?

Does the media favor VTRS or ARGX?

Do insiders & institutionals have more ownership in VTRS or ARGX?

Do analysts prefer VTRS or ARGX?

Is VTRS or ARGX more profitable?

Which has higher earnings and valuation, VTRS or ARGX?

Summary

How does Viatris compare to Teva Pharmaceutical Industries?

Which has more risk & volatility, VTRS or TEVA?

Does the media favor VTRS or TEVA?

Do insiders and institutionals hold more shares of VTRS or TEVA?

Is VTRS or TEVA a better dividend stock?

Do analysts prefer VTRS or TEVA?

Is VTRS or TEVA more profitable?

Which has preferable earnings & valuation, VTRS or TEVA?

Summary

How does Viatris compare to BeOne Medicines?

Does the media prefer ONC or VTRS?

Which has more risk and volatility, ONC or VTRS?

Which has preferable valuation & earnings, ONC or VTRS?

Is ONC or VTRS more profitable?

Do analysts recommend ONC or VTRS?

Do insiders and institutionals hold more shares of ONC or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTRS vs. The Competition

Viatris Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools